PEG-Intron/Rebetol Subgroups Should Be Analyzed, Cmte. Says
FDA's Antiviral Drugs Advisory Committee would like to see an analysis of patient subgroups treated with Schering-Plough's PEG-Intron (peginterferon alfa-2b) and Rebetol (ribavirin)
FDA's Antiviral Drugs Advisory Committee would like to see an analysis of patient subgroups treated with Schering-Plough's PEG-Intron (peginterferon alfa-2b) and Rebetol (ribavirin)